All In Biotech

Drug Trial Radar · NCT00995150

A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

A Phase 3, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

Last checked: Nov 20, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,910 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,910

Actual

Start

Nov 2009

Primary completion

Oct 12, 2021

Study completion Oct 12, 2021

Sponsor

Lead sponsor
Medicines360Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 15, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 16 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who request long-term, reversible contraception for up to 10 years.

Conditions

  • Contraception

Interventions

  • LNG20Drug

    levonorgestrel-releasing intrauterine system for contraception

  • MirenaDrug

    Mirena intrauterine system

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Pregnancies Per YearTime frame: 10 years
  2. Cumulative Pearl IndexTime frame: 8 years

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Palo Alto, California

  • Site not named

    San Francisco, California

  • Site not named

    Vista, California

  • Site not named

    Denver, Colorado

  • Site not named

    Atlanta, Georgia

  • Site not named

    Idaho Falls, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Des Moines, Iowa

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    New York, New York

  • Site not named

    Chapel Hill, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Tulsa, Oklahoma

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Magee Women's Hospital, University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Site not named

    Dallas, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Norfolk, Virginia

  • Site not named

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.